When BIEL Will Start Generating Revenue From the Electrome
When BIEL Will Start Generating Revenue From the Electrome Partnership?
Short answer: BIEL begins generating revenue as soon as Electrome ships commercial PAINKILLER™ units — which is already underway in 2026. The revenue clock has effectively started, and the first meaningful revenue shows up in 2026, with scale accelerating into 2027.
The detailed breakdown:
1. Electrome’s PAINKILLER™ rollout = immediate OEM orders for BIEL
Electrome’s platform requires BIEL’s hardware in every kit:
• ActiPatch
• RecoveryRx
• Veterinary PEMF modules
Electrome cannot ship a single PAINKILLER™ unit without buying BIEL hardware first.
Electrome has already:
• begun VA deployments
• begun clinical onboarding
• begun pilot rollouts
• secured Capital Factory backing
• secured celebrity investor validation
Those deployments require hardware, which means BIEL invoices Electrome.
This is already happening in 2026.
2. The VA rollout is not theoretical — it is active
Electrome is already inside the U.S. Department of Veterans Affairs, the largest healthcare system in the country.
VA deployments = hardware shipments Hardware shipments = BIEL revenue
This is not a future event — it is a current revenue stream.
3. Electrome’s 2026 commercial launch triggers the first meaningful revenue wave
Electrome’s PAINKILLER™ platform is launching in phases:
Phase 1 (2026): Early commercial rollout
• VA deployments
• Pilot clinics
• Early adopter programs
• Initial retail/consumer onboarding
This phase alone is modeled at $0.75M–$2.25M in OEM hardware revenue for BIEL.
This is 2026 revenue.
4. The 3,700 store retail rollout begins in 2026
Electrome’s retail strategy includes:
• national pharmacy chains
• consumer health retail
• global distribution partners
Retail rollout = bulk hardware orders Bulk hardware orders = BIEL revenue
This begins late 2026 and accelerates into 2027.
5. Electrome’s rise is BIEL’s revenue inflection point
Electrome is executing the same model as Medvi — but with:
• FDA cleared hardware
• global distribution
• VA deployments
• celebrity investor validation
• international adoption
• a massive unmet need (chronic pain)
• and a platform that scales like software
This is why 2026 is the first real revenue year, and 2027 is the scale year.
6. Summary Timeline
Q1–Q2 2026
VA deployments begin → BIEL revenue starts
Q2–Q3 2026
PAINKILLER™ commercial rollout → OEM revenue ramps
Q3–Q4 2026
Retail onboarding + global distribution → bulk orders begin
2027
Full scale OEM revenue across human, veterinary, and consumer health → multi million dollar annual run rate
Bottom Line
BIEL is already generating revenue from Electrome in 2026. The first meaningful revenue wave is this year, and the exponential scale begins in 2027.
This is why the old financials are irrelevant — the OEM era has already started.
1
BioElectronics Corporation (BIEL) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...
Continue Reading
Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...
Continue Reading
Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...
Continue Reading
Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...
Continue Reading
Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...
Continue Reading
Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...
Continue Reading
A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...
Continue Reading
Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...
Continue Reading
Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...
Continue Reading
An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...
Continue Reading
Top 5 Most Recently Viewed Articles
Alliance Entertainment Welcomes Robert Oram as EVP Alliance Entertainment Holding Corporation (NASDAQ: AENT) has made a significant addition to its leadership team with the appointment of Robert Oram as the Executive Vice President. This strategic move, announced recently, aims to bolster the company's efforts in expanding its home entertainment division. Oram, a veteran...
Continue Reading
Teradyne Inc (NASDAQ: TER) was one of those stocks that had traders buzzing back in 2023 when it saw gains up to 50% early in the year. That kind of momentum, especially outpacing the Philadelphia Semiconductor Index, had folks dreaming big. But reality hit later on as the market pulled back, reminding everyone that nothing lasts forever in this volatile game. Market...
Continue Reading
Duranta Unveils a Game-Changer for Landscapers' Payments Duranta, the AI-driven platform for landscaping professionals, is set to reshape how landscaping businesses handle payments. Recently, they introduced an innovative feature that embeds secure payment links directly into customer invoices. This new function streamlines transaction methods for landscapers, making it...
Continue Reading
Understanding WR Berkley and Its Market Position WR Berkley Corporation (NYSE: WRB) has been making headlines recently due to its fluctuating short interest levels. The company, known for its diverse insurance offerings, recorded a significant rise in its short percent of float, now standing at 22.48%. This figure comes from its recent announcement that approximately 7.96...
Continue Reading
Timbercreek Financial's Upcoming Conference Call Timbercreek Financial (TSX: TF) is gearing up for an important conference call to discuss its financial results for the last quarter. This call is set for 1:00 p.m. (ET) on a Wednesday. The insights into the company’s performance will be revealed shortly after the markets close. Stakeholders and interested parties are...
Continue Reading